NEW YORK (
CHANGE IN RATINGS
upgraded at Credit Suisse to Outperform from Neutral on increased gold price forecasts. Price target lifted to $54 from $47.
downgraded at Barclays to Equal Weight from Overweight. Valuation call. Price target held at $15.
Bank of Hawaii
reinstated at BofA/Merrill with a Neutral rating. The company has demonstrated strong profitability while note participating in TARP or cutting its dividend, but that's already priced into shares. $49 price target.
downgraded at Argus from Buy to Hold. Recent slowdown in cruise demand could weigh on the stock.
downgraded at BofA/Merrill to Neutral from Buy as flooding damages need time and money to be repaired. Price target dropped to $62 from $68.
Stock Ratings 10 Sell-Rated Stocks Under $5
rated new Buy at Kaufman Bros. $30 price target. Company is positioned well to benefit from industry trends.
upgraded at Sterne Agee from Sell to Neutral. Company is positioned well to benefit from a rally in 10-year bonds.
downgraded at Leerink to Market Perform. Stock has outperformed the past few months and appears to have limited upside potential.
downgraded at Janney from Buy to Neutral. Recovery in the housing market remains elusive. $30 price target.
upgraded at Leerink from Market Perform to Outperform. Stock has pulled back and the company has the best volume growth in the industry.
estimates, target boosted at UBS. Shares of KMX now seen reaching $23. Estimates also upped, given higher realize margins. Sell rating.
upgraded at UBS from Neutral to Buy. $28 price target. Estimates also boosted, given better pricing and higher expected income from auto financing.
Grand Canyon Education
rated new Outperform at Baird. $33 price target. Company can deliver 25%-plus annual growth over the next three years.
downgraded at Janney from Buy to Neutral. $22 price target. Housing sales should drop off, following the end of government stimulus.
upgraded at FBR from Underperform to Market Perform. $41 price target. Company offers investors safety.
Pinnacle West Capital
upgraded at Barclays to Overweight from Equal Weight as the company is leveraged to a pick up in the Phoenix economy. Price target raised to $40.
upgraded at Deutsche from Hold to Buy. $30 price target. Potential overhangs have been lifted from the stock.
downgraded at Keybanc from Buy to Hold. Company derives more than half of its sales from Europe.
upgraded at Davenport from Neutral to Buy. $15 price target. Stock is down 40% over the past two months, creating an attractive entry point.
upgraded at Sterne Agee from Buy to Neutral. $115 price target. Company should continue to post solid growth in Macau.
STOCK COMMENTS / EPS CHANGES
Bed Bath & Beyond
price target cut at Barclays by a dollar to $46. Strong 1Q10 results but weak guidance. Equal Weight rating.
estimates cut at Morgan Stanley through 2011. Higher spot rates could hurt earnings, but this is likely already priced into the stock. Equal-weight rating.
price target changed at Barclays. DHR price target adjusted to $50 from $100 to account for stock split. Overweight rating.
numbers cut at Goldman through 2012. SSPD has been suspended from receiving any new contracts. Sell rating and new $69 price target.
estimates lowered at UBS through 2012. Margin pressures are mounting. Neutral rating and $77 price target.
price target lower at Barclays by a dollar to $28 on positive 4Q10 results but weak 1Q11estimates. Equal Weight rating.
price target cut at Credit Suisse to $21 from $22 as launch of pain relief drug, Tanezumab, was pushed back. Maintain Outperform rating.
numbers increased at UBS. Shares of PXD now seen reaching $70, according to UBS. Estimates also raised, given the recent asset sale. Neutral rating.
estimates, target boosted at Sterne Agee. Shares of SNDK now seen reaching $55. Estimates also upped, given the strength of new product cycles. Buy rating.
target raised at Morgan Stanley to $21. Company appears to be supplying more components to Apple. Overweight rating.
This article was written by a staff member of TheStreet.com.